Dear our wonderful patients and parents,
We are happy to announce that we re-opened starting June 1st, 2020 per Santa Clara County Board of Supervisors and our Public Health Officer. Thank you so much for your support and understanding during this difficult time.
Please note that as a result of COVID-19, we have updated some of our daily procedures. You’ll still receive the same great service from our dedicated team, however to ensure the safety of all our patients we’ve implemented some changes mentioned in the previous message that you will find below.
Again, thank you so much for your support. We’re happy to continue serving you, and can’t wait to see your smile!
Your dental family at San Jose Dental Specialists
Dr. Daniel Nguyen, Dr. Suzanne Nguyen, and Team
PATIENT SCREENING FORMS
We ask that our patients fill out the
Yes. Everyone 12 or older who lives, works, or studies in New Jersey is now eligible for the COVID-19 vaccine.
If you are uninsured, you can still receive a vaccine. The vaccine is free – there is no cost to you. Learn more about insurance coverage for COVID-19 vaccines here. If you are insured, you are encouraged to bring your insurance information so that the site can get reimbursed at no cost to you.
Documentation is not required to be vaccinated. Vaccine sites may request documentation, but you are not required to have it to receive the vaccine and you cannot be denied access to the vaccine for not having ID. Sites will NOT ask for proof of immigration status.
U.S. Immigration and Customs Enforcement (ICE) and U.S. Customs and Border Protection will not conduct enforcement operations at or near vaccine distribution sites or clinics.
Any data collected for the
Saudi Gazette report
MANAMA — Bahrain’s National Health Regulatory Authority (NHRA) has approved REGN-COV2 for emergency use, a new drug by Regeneron in collaboration with F. Hoffmann-La Roche, for the treatment of mild to moderate COVID-19 cases, the Bahrain News Agency reported on Wednesday.
REGN-COV2 contains a combination of Casirivimab and Imdevimab, which are drugs called “monoclonal antibodies,” that are designed to block viral attachment and entry into human cells to neutralize the virus.
REGN-COV2 also received emergency use approval from the US FDA to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents of 12 years of age and older, who weigh at least 88 pounds (40 kg), and for those who are at high risk for developing severe COVID-19 symptoms or of hospitalization.
REGN-COV2 also received a positive review from the European Medicines Agency after their analysis of the quality, safety, and efficacy aspects of
The swift development of vaccines has provided a vital tool to combat the spread of the deadly SARS-CoV-2 virus, but challenges to reaching herd immunity posed by the rise of new mutations and the inability of immunosuppressed people to develop an effective immune response following vaccination point to a need for additional solutions to maximize protection.
A new study by Keck School of Medicine (KSOM) researchers published in the Journal of Biological Chemistry reveals how therapies targeting a molecular chaperone called GRP78 might offer additional protection against COVID-19 and other coronaviruses that emerge in the future.
Chaperones like GRP78 are molecules that help regulate the correct folding of proteins, especially when a cell is under stress. But in some
Ivermectin resulted in a reduction of virus replication in laboratory studies, the university said, adding that a small pilot showed giving the drug early could reduce viral load and the duration of symptoms in some patients with mild Covid-19.
Dubbed PRINCIPLE, the British study in January showed that antibiotics azithromycin and doxycycline were generally ineffective against early-stage Covid-19.
While the World Health Organization, and European and US regulators have recommended against using ivermectin in Covid-19 patients, it is being used to treat the illness in some countries, including India.
“By including ivermectin in a large-scale trial like PRINCIPLE, we hope to generate robust evidence to determine how effective the treatment is against Covid-19, and
Last Updated: February 11, 2021
Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug that is used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.1 It is also being evaluated for its potential to reduce the rate of malaria transmission by killing mosquitoes that feed on treated humans and livestock.2 For these indications, ivermectin has been widely used and is generally well tolerated.1,3 Ivermectin is not approved by the FDA for the treatment of any viral infection.
Proposed Mechanism of Action and Rationale for Use in Patients With COVID-19
Reports from in vitro studies suggest that ivermectin acts by inhibiting the host importin alpha/beta-1 nuclear transport proteins, which are part of a key intracellular transport process that viruses hijack to enhance infection by suppressing the host’s antiviral response.4,5 In addition, ivermectin docking may interfere with
- Docket Number:
- Issued by:
Guidance Issuing Office
Oncology Center of Excellence
Center for Biologics Evaluation and Research
Center for Drug Evaluation and Research
FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic.
FDA is issuing this guidance to provide recommendations to sponsors of master protocols evaluating drugs for the treatment or prevention of COVID-19.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document’s docket number: FDA-2021-D-0409.
- In urban areas, the electronic vaccination data system (EVDS) will allocate a site within 10km of your work or home. In rural areas, it will be within 30km of the address you entered.
- The system won’t allow you to register if you’re not a health worker or over 60, until the health department opens up the next category for registration.
- A list of vaccination sites will soon be published on the government’s coronavirus website and will be updated each week.
This week, the EVDS sent out the country’s first text messages for Covid-19 vaccination appointments – but not without problems.
All the healthcare workers, and people of 60-years-old or older, who received messages got the notifications on short notice, mostly the afternoon or night before the day of their appointments. This resulted in many of them being unable to make the appointments and led to questions on social media about
If you are unable to leave the home to receive a COVID-19 vaccine or are the healthcare provider or family caregiver of someone who is homebound, you may request an in-home vaccination appointment by completing a form at covid19.nj.gov/homeboundvax (English) or covid19.nj.gov/homeboundvax-es (Spanish).
For assistance completing the form by phone, please call the NJ COVID-19 Vaccine Call Center at 1-855-568-0545.
After you submit the completed form, the NJ Department of Health will share information with a home health agency, local health department, or other vaccination providers and you will be contacted to schedule an in-home vaccination appointment.
If there are any unvaccinated household or family members in need of vaccination, vaccine providers will also do their best to schedule vaccination for caregivers and other members of the household of homebound person(s). Please confirm this need in the online form .
Some home health agencies are currently vaccinating patients—if you are
Zambian President Edgar Lungu.
- Zambia has banned campaign rallies ahead of elections scheduled for August.
- The country has recorded more than 93 000 confirmed cases of Covid-19, with more than 1 200 deaths.
- A leader of the opposition party said his party would go ahead with its campaign rallies.
Zambian President Edgar Lungu on Wednesday banned campaign rallies ahead of elections scheduled for 12 August, saying large gatherings risked spreading the Covid-19 virus.
Lungu, a lawyer, is pitted against economist Hakainde Hichilema of the United Party for National Development (UPND), whom he narrowly beat in the 2016 elections.
Zambia, Africa’s no.2 copper producer, is the grips of an economic crisis after it failed to make payment of a coupon on one of its dollar bonds in November, dragging it into sovereign default.
Opposition parties have pilloried Lungu’s handling of the crisis. Last year, police shot dead two people after